Genomic landscape of HIV-1 proviruses in ART-treated immunological non-responders - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Genetic Profiling of HIV-1 Proviruses in Immunological Non-Responders Under Antiretroviral Therapy

  • By

  • Shengquan Tang

  • Yue Wang

  • Yanqiu Lu

  • Zhen Tong

  • Jiahui Guo

  • Yizhi Cui

  • Vijay Harypursat

  • Yemiao Chen

  • Jing Ouyang

  • Huan Li

  • Tong Wang

  • Quanhua Zhou

  • Yaokai Chen

  • August 12, 2026

Share

  • 1

    The study investigates the genetic characteristics of HIV-1 proviruses in immunological non-responders (INRs) and responders (IRs) on antiretroviral therapy.

  • 2

    INRs exhibited higher levels of intact proviral genomes compared to IRs, indicating a distinct proviral landscape despite similar levels of defective proviruses.

  • 3

    Defective proviruses comprised the majority of the reservoir in both INRs and IRs, with defects primarily located in the 3′ half of the genome.

  • 4

    The research utilized near-full-length HIV-1 DNA amplification and third-generation sequencing to analyze proviral genomes in peripheral blood mononuclear cells.

  • 5

    Findings suggest that the intact proviral reservoir may play a role in the insufficient immune reconstitution observed in INRs.

Original Source(s)

Genomic landscape of HIV-1 proviruses in ART-treated immunological non-responders

  • by Shengquan Tang, Yue Wang, Yanqiu Lu, Zhen Tong, Jiahui Guo, Yizhi Cui, Vijay Harypursat, Yemiao Chen, Jing Ouyang, Huan Li, Tong Wang, Quanhua Zhou, Yaokai Chen

  • August 12, 2026

Related Content

Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal

Endogenous Endophthalmitis and Missed Diagnoses

Retrospective study describes how endogenous endophthalmitis often presents without systemic symptoms

  • July 21, 2026

  • 3 min
Oral Shigella Vaccine Hits 89% Efficacy in Challenge Trial

An investigational oral Shigella sonnei vaccine showed robust protection against shigellosis in a phase 2 controlled human infection trial.